In part 5, the conclusion of this Exclusive Interview, Kathleen Wyne talks with Diabetes in Control Medical Editor Joy Pape during the AACE 2018 convention in Boston, MA about starting statins in adults with type 1.

Results suggest the need for screening, surveillance in survivors

Use of acute care service five-fold higher after interruption in insurance versus before interruption

This week, it is all about devices, and how they look to change the way we manage diabetes. First off, we have a new device that seems to work similar to the V-Go insulin delivery system. This device becomes the 3rd “mechanical pump” that will be available to patients and, …

Getting diabetes in our later years increases risk for CVD, but getting diabetes or prediabetes as a youth increases risk for CVD and death dramatically.

New study shows that within the first two years of a diagnosis of cancer, the risk for type 2 diabetes increases.

The Omnipod Dash™ device approved for commercialization and release in the U.S. by mid-2018.

Addition of glucagon prevents exercise-induced hypoglycemia.

Guest Post by David Kliff, Editor, Diabetic Investor

With each passing day, it’s becoming more apparent that CGM will replace BGM as the standard for glucose measurement. CGM systems are becoming more patient-friendly, i.e. no calibrations, simple insertion, and cheaper too. The data provided by CGM is transformative, leading to improved outcomes. It is no longer a question of if this will happen but when this will happen.

Would you be open to using a CGM for your type 2 patients who are not on insulin? Follow the link to share your response.